Ginkgo Bioworks Holdings Inc vs Skyworks Solutions Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.17 (market cap $590.53M), while Skyworks Solutions Inc trades at $57.96 (market cap $8.51B). The key difference: Skyworks Solutions Inc is far larger — about 14.4× Ginkgo Bioworks Holdings Inc's market cap, and Skyworks Solutions Inc pays a 5.02% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | SWKS | |
|---|---|---|
Market Cap | $590.53M | $8.51B |
Sector | Health | Technology |
52-Week High | $16.14 | $83.40 |
52-Week Low | $5.48 | $52.50 |
Enterprise Value | $627.78M | $8.28B |
Dividend Yield | — | 5.02% |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Skyworks Solutions (SWKS) trades at $58.24, down 3.51% amid bearish technical signals, though recent earnings beats and a 60% analyst buy rating suggest underlying strength. The company maintains solid fundamentals with $4.09B revenue and 8.93% net margin, while expanding into AI and EV markets through recent product launches. Cash flow trends show variability, with 2025 net cash flow negative at -$207M after positive flows in prior years.
The stock presents a value opportunity with consensus price target of $72.56 offering 25% upside, supported by dividend yield above 4% and strategic positioning in growing semiconductor segments. Key risks include ongoing legal investigations and customer concentration, but strong analyst support and technical oversold conditions near support at $55 indicate potential for recovery.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →